These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1152 related articles for article (PubMed ID: 21388048)

  • 1. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
    Gonçalves A; Sabatier R; Charafe-Jauffret E; Gilabert M; Provansal M; Tarpin C; Extra JM; Viens P; Bertucci F
    Bull Cancer; 2013 May; 100(5):453-64. PubMed ID: 23695030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential prognostic tumor biomarkers in triple-negative breast carcinoma.
    Peng Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):666-72. PubMed ID: 23073572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of triple negative breast cancer.
    Oakman C; Viale G; Di Leo A
    Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
    Curigliano G; Goldhirsch A
    J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?
    Petrelli F; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1467-77. PubMed ID: 19737114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of triple-negative breast cancer.
    de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: an unmet medical need.
    Hudis CA; Gianni L
    Oncologist; 2011; 16 Suppl 1():1-11. PubMed ID: 21278435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
    Tang P; Tse GM
    Arch Pathol Lab Med; 2016 Aug; 140(8):806-14. PubMed ID: 27472239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel treatment approaches for triple-negative breast cancer.
    Telli ML; Ford JM
    Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.